{"protocolSection": {"identificationModule": {"nctId": "NCT00413413", "orgStudyIdInfo": {"id": "CVAA489A2316"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension", "officialTitle": "A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controled, Parallel Study, Comparing Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Valsartan 80 mg and Valsartan 160 mg Alone Once Daily in Patients With Mild to Moderate Essential Hypertension Not Adequately Controlled With Valsartan 80 mg Monotherapy."}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-12-18", "studyFirstSubmitQcDate": "2006-12-18", "studyFirstPostDateStruct": {"date": "2006-12-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-06", "resultsFirstSubmitQcDate": "2009-08-06", "resultsFirstPostDateStruct": {"date": "2009-09-14", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-26", "lastUpdatePostDateStruct": {"date": "2011-04-28", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension, valsartan, amlodipine, high blood pressure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1134, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan/amlodipine 80/5 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan/amlodipine 80/5 mg"]}, {"label": "Valsartan 80 mg", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Valsartan 80 mg"]}, {"label": "Valsartan 160 mg", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Valsartan 160 mg"]}], "interventions": [{"type": "DRUG", "name": "Valsartan/amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily", "armGroupLabels": ["Valsartan/amlodipine 80/5 mg"]}, {"type": "DRUG", "name": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily", "armGroupLabels": ["Valsartan 80 mg"]}, {"type": "DRUG", "name": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily", "armGroupLabels": ["Valsartan 160 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "timeFrame": "Baseline to end of study (Week 8)"}], "secondaryOutcomes": [{"measure": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)", "description": "A diastolic blood pressure response was defined as a msDBP \\< 90 mmHg or a \u2265 10 mmHg decrease compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "timeFrame": "Baseline to end of study (Week 8)"}, {"measure": "Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)", "description": "Diastolic blood pressure control was defined as a msDBP \\< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "timeFrame": "End of study (Week 8)"}, {"measure": "Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)", "description": "Overall blood pressure control rate was defined as a msSBP/msDBP \\< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "timeFrame": "End of study (Week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female outpatients \\>= 18 years and \\< 86 years\n* Patients with essential diastolic hypertension\n* At visit 1, the patient must have mean sitting diastolic blood pressure \\>= 95 mmHg and \\< 10 mmHg; patients treated with antihypertensive medication must have a mean sitting diastolic blood pressure \\< 100 mmHg\n* At visit 2, patients must have a mean sitting diastolic blood pressure of \\>= 95 mmHg and \\< 100 mmHg\n* At visit 3, patients must have a mean sitting diastolic blood pressure of \\>= 90 mmHg and \\< 110 mmHg\n\nExclusion Criteria:\n\n* Severe hypertension \\>= 180/110 mmHg\n* Known or suspected contraindications, including a history of allergy or hypersensitivity to valsartan or amlodipine or to other drugs with similar chemical structures\n* Inability to discontinue all prior antihypertensive medications safely for a maximum period of up to 28 days prior to Visit 2\n* History of hypertensive encephalopathy, cerebrovascular accident or transient ischemic attack, myocardial infarction or other types of revascularization\n* Malignant hypertension\n* All patients with Type I diabetes and those patients with Type 2 diabetes who are not well controlled based on the investigator's clinical judgment\n* Pregnant or nursing women\n* History of heart failure\n* Angina pectoris\n* Second or third degree heart block\n* Life threatening or symptomatic arrhythmias\n* Clinically significant valvular heart disease\n* Evidence of a secondary form of hypertension\n* Known or moderate malignant retinopathy\n* Evidence of hepatic disease\n* Evidence of renal impairment\n\nOther protocol-defined exclusion criteria may apply.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Beijing ChaoYang Hospital, Affiliate of Capital University of Medical Sciences", "city": "Beijing", "zip": "100020", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Beijing General Hospital of Beijing Military Region", "city": "Beijing", "zip": "100700", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Beijing Hospital", "city": "Beijing", "zip": "100730", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "The First People's Hospital of Hangzhou", "city": "Hangzhou", "zip": "310006", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "The Second Affiliated Hospital of Medical College of Zhejiang University", "city": "Hangzhou", "zip": "310006", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "The First Affiliated Hospital of Medical College of Zhejiang University", "city": "Hangzhou", "zip": "310007", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Southeast University Affiliated Zhong Da Hospital", "city": "Nanjing", "zip": "210009", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "The First Affiliated Hospital of Nanjing Medical University", "city": "Nanjing", "zip": "210029", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Second Military Medical University Affiliated Changzheng Hospital", "city": "Shanghai", "zip": "200003", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Department of cardiology, Ruijin hospital;", "city": "Shanghai", "zip": "200025", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Department of cardiology, Ruijin hospital", "city": "Shanghai", "zip": "200025", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Fudan University affiliated zhongshan hospital", "city": "Shanghai", "zip": "200032", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Second Military Medical University Affiliated Changhai Hospital", "city": "Shanghai", "zip": "200433", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "The First Affiliated Hospital of China Medical University", "city": "Shenyang", "zip": "110001", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "The people's Hospital of Liaoning Province", "city": "Shenyang", "zip": "110016", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Second Hospital of Hebei University of Medical Sciences", "city": "Shijiazhuang", "zip": "050050", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "The People's Hospital of Hebei Provincial", "city": "Shijiazhuang", "zip": "050051", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "The Second Affiliated Hospital of Soochow University", "city": "Suzhou", "zip": "215004", "country": "China", "geoPoint": {"lat": 31.30408, "lon": 120.59538}}, {"facility": "The First Affiliated Hospital of Soochow University", "city": "Suzhou", "zip": "215006", "country": "China", "geoPoint": {"lat": 31.30408, "lon": 120.59538}}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "A total of 1134 patients were enrolled into the single-blind period of the study, and 216 (19%) were discontinued. In total, 918 patients were randomized to the three treatment groups.", "groups": [{"id": "FG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "FG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "FG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}], "periods": [{"title": "Single-Blind", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "In single-blind period participants were only enrolled to Valsartan 80 mg arm.", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1134"}, {"groupId": "FG002", "comment": "In single-blind period participants were only enrolled to Valsartan 80 mg arm.", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "918"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "216"}, {"groupId": "FG002", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Subject no longer requires study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "151"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "16"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "27"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "0"}]}]}, {"title": "Double-Blind", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "308"}, {"groupId": "FG001", "numSubjects": "307"}, {"groupId": "FG002", "numSubjects": "303"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "293"}, {"groupId": "FG001", "numSubjects": "293"}, {"groupId": "FG002", "numSubjects": "285"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "15"}, {"groupId": "FG001", "numSubjects": "14"}, {"groupId": "FG002", "numSubjects": "18"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Subject withdrew consent", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "BG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "BG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "308"}, {"groupId": "BG001", "value": "306"}, {"groupId": "BG002", "value": "302"}, {"groupId": "BG003", "value": "916"}]}], "measures": [{"title": "Age Continuous", "description": "All baseline measures were based on Full-set analysis population. Two patients were excluded from the full-set analysis population for having no post-baseline efficacy assessment. All randomized patients were included in the safety population.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.6", "spread": "10.8"}, {"groupId": "BG001", "value": "51.7", "spread": "8.9"}, {"groupId": "BG002", "value": "51.2", "spread": "9.6"}, {"groupId": "BG003", "value": "51.5", "spread": "9.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "127"}, {"groupId": "BG001", "value": "115"}, {"groupId": "BG002", "value": "104"}, {"groupId": "BG003", "value": "346"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "181"}, {"groupId": "BG001", "value": "191"}, {"groupId": "BG002", "value": "198"}, {"groupId": "BG003", "value": "570"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "populationDescription": "Full-set analysis population: All randomized patients who had a baseline and at least one post-baseline efficacy measurement. For patients who did not complete the Week 8 assessment, a last observation carried forward (LOCF) approach was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "OG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "OG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "306"}, {"groupId": "OG002", "value": "302"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-10.8", "spread": "0.42"}, {"groupId": "OG001", "value": "-6.3", "spread": "0.42"}, {"groupId": "OG002", "value": "-7.2", "spread": "0.42"}]}]}]}, {"type": "SECONDARY", "title": "Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)", "description": "Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "populationDescription": "Full-set analysis population population: All randomized patients who had a baseline and at least one post-baseline efficacy measurement. For patients who did not complete the Week 8 assessment, a last observation carried forward (LOCF) approach was used.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "OG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "OG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "306"}, {"groupId": "OG002", "value": "302"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.5", "spread": "0.61"}, {"groupId": "OG001", "value": "-6.0", "spread": "0.62"}, {"groupId": "OG002", "value": "-7.7", "spread": "0.62"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving a Diastolic Blood Pressure Response at the End of the Study (Week 8)", "description": "A diastolic blood pressure response was defined as a msDBP \\< 90 mmHg or a \u2265 10 mmHg decrease compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "populationDescription": "Full-set analysis population: All randomized patients who had a baseline and at least one post-baseline efficacy measurement. For patients who did not complete the Week 8 assessment, a last observation carried forward (LOCF) approach was used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "Baseline to end of study (Week 8)", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "OG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "OG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "306"}, {"groupId": "OG002", "value": "302"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "77.9"}, {"groupId": "OG001", "value": "57.8"}, {"groupId": "OG002", "value": "66.6"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Diastolic Blood Pressure Control at the End of the Study (Week 8)", "description": "Diastolic blood pressure control was defined as a msDBP \\< 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "populationDescription": "Full-set analysis population: All randomized patients who had a baseline and at least one post-baseline efficacy measurement. For patients who did not complete the Week 8 assessment, a last observation carried forward (LOCF) approach was used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "OG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "OG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "306"}, {"groupId": "OG002", "value": "302"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.4"}, {"groupId": "OG001", "value": "53.6"}, {"groupId": "OG002", "value": "64.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Overall Blood Pressure Control at the End of the Study (Week 8)", "description": "Overall blood pressure control rate was defined as a msSBP/msDBP \\< 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated.", "populationDescription": "Full-set analysis population: All randomized patients who had a baseline and at least one post-baseline efficacy measurement. For patients who did not complete the Week 8 assessment, a last observation carried forward (LOCF) approach was used.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of patients", "timeFrame": "End of study (Week 8)", "groups": [{"id": "OG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily"}, {"id": "OG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}, {"id": "OG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "308"}, {"groupId": "OG001", "value": "306"}, {"groupId": "OG002", "value": "302"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "70.5"}, {"groupId": "OG001", "value": "44.1"}, {"groupId": "OG002", "value": "58.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Valsartan/Amlodipine 80/5 mg", "description": "1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily", "seriousNumAffected": 4, "seriousNumAtRisk": 308, "otherNumAffected": 0, "otherNumAtRisk": 308}, {"id": "EG001", "title": "Valsartan 80 mg", "description": "1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily", "seriousNumAffected": 0, "seriousNumAtRisk": 307, "otherNumAffected": 0, "otherNumAtRisk": 307}, {"id": "EG002", "title": "Valsartan 160 mg", "description": "1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily", "seriousNumAffected": 4, "seriousNumAtRisk": 303, "otherNumAffected": 0, "otherNumAtRisk": 303}], "seriousEvents": [{"term": "Leukopenia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 308}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 307}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 303}]}, {"term": "Retinal haemorrhage", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 308}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 307}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 303}]}, {"term": "Abdominal injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 308}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 307}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 303}]}, {"term": "Liver function test abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 308}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 307}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 303}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 308}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 307}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 303}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 308}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 307}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 303}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862 778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000068756", "term": "Valsartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}